Skip to main content

Closed

DRMA: Dermata Therapeutics, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+0.0% / yr

Operating margin0.0%

ROIC-114.8%

Financially safe

Stretched

Debt / equity0.00×

Interest coverage0.0×

Current ratio7.09×

Dermata Therapeutics, Inc.

DRMANASDAQ Capital Market·USD·Closed

Dermata Therapeutics, Inc.

DRMANASDAQ·USD·Closed

$1.17

−0.85%

$1.17

−$0.01 (0.85%)

52W Range

1thpctl

Volume

1.25×avg

Mkt Cap

797422USD

P/E

-0.2TTM

Div Yield

–ann

52W Range

1thpctl

Volume

1.25×avg

Market Cap

797422USD

P/E Ratio

-0.2TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings